TABLE 1.
Recurrent Gene Fusions in Prostate Cancer
| Gene Fusion | Sample | Frequency (%) | Fusion Type | Assay | Study |
|---|---|---|---|---|---|
| TMPRSS2:ERG | PCA | 16/29 (55%) | T1:E4 | qRT-PCR/FISH | Tomlins, et al 20051 |
| TMPRSS2:ETV1 | PCA | 7/29 (24%) | T1:E4 | ||
| TMPRSS2:ERG | PCA, biopsy | 14/18 (77%) | T1:E4, T1:E2, T4/5:E4/5 | Nested RT-PCR | Soller, et al 20062 |
| TMPRSS2:ETV4 | PCA, overexpressing ETS family genes | 2/98 (2%) | RACE/qRT-PCR/FISH | Tomlins, et al 20063 | |
| TMPRSS2:ERG | PCA, Gleason score 6–9 | 6/15 (40%) | T1:E5, T2:E5, T1:E4 | RT-PCR/FISH | Yoshimoto, et al 20064 |
| TMPRSS2:ERG | PCA | 58/118 (49%) | FISH/qRT-PCR | Perner, et al 20065 | |
| TMPRSS2:ERG | PCA | 7/18 (41%) | |||
| TMPRSS2:ERG | PCA | 35/59 (59%) | 8 different types of fusions | RT-PCR | Wang, et al 20066 |
| TMPRSS2:ERG | BPH | 0/20 (_) | |||
| TMPRSS2:ERG | PCA, T1cN0M0/T2N0M0 | 17/34 (50%) | T1:E4 | RT-PCR/qRT-PCR | Cerviera, et al 20067 |
| TMPRSS2:ERG | HGPIN | 4/19 (21%) | |||
| TMPRSS2:ERG | BPH | 0/13 (_) | |||
| TMPRSS2:ERG | Normal Prostate | 0/11 (_) | |||
| TMPRSS2:ERG | PCA | 19/26 (73%) | T1:E4, T1:E5. T1:E2, T1:E3, etc.-total 14 types | RT-PCR/Nested-PCR | Clark, et al 20078 |
| TMPRSS2:ERG | Normal adjacent | 8/17 (47%) | |||
| TMPRSS2:ERG | BPH | 2/31 (6%) | |||
| TMPRSS2:ERG | Non-Prostate Normal | 0/20 (_) | |||
| TMPRSS2:ERG | Post:DRE Urine | 8/19 (42%) | T1:E4 (5) T1:32 (1) | qRT-PCR/FISH | Laxman, et al 20069 |
| TMPRSS2:ERG | PCA, Advanced | 7/19 (37%) | T2:E6;E4 (1) | RT-PCR/array cGH | Iljin, et al 200610 |
| TMPRSS2:ETV4 | PCA, Advanced | 2/18 (11%) | T1/2:E4 | ||
| TMPRSS2:ERG TMPRSS2:ETV1 |
PCA, Xenografts PCA, Xenografts |
5/11 (45%) 1/11 (9%) |
T1/2:E5 | FISH/qPCR | Hermans, et al 200611 |
| TMPRSS2:ERG | PCA, Gleason score 7 | 11/26 (42%) | RT-PCR, Sequencing | Nami, et al 200712 | |
| TMPRSS2:ERG | PCA, T1a:b, Ns, M0′, Orebro Watchful Waiting Cohort | 17/111 (15%) | FISH/qRT-PCR | Demichelis, et al 200713 | |
| TMPRSS2:ERG | PCA | 36/101 (36%) | T2:E4 and T1:E4 | FISH/RT-PCR, Sequencing | Rajput, et al 200714 |
| TMPRSS2:ERG | BHP | 0/5 (_) | |||
| TMPRSS2:ERG | PCA | 30/56 (54%) | FISH | Mehra, et al 200715 | |
| TMPRSS2:ETV1 | PCA | 1/53 (2%) | |||
| TMPRSS2:ETV4 | PCA | 1/58 (2%) | |||
| TMPRSS2:ERG | PCA | 44/63 (70%) | T2:E4 & T2:E4* | RACE/qRT-PCR/FISH | Lapointe, et al 200716 |
| TMPRSS2:ERG | PCA | 120/253 (47%) | FISH | Mosquera, et al 200717 | |
| TMPRSS2:ERG | PCA | 18/50 (36%) | RT-PCR | Winnes, et al 200718 | |
| TMPRSS2:ERG | PCA | 115/237 (48%) | FISH | Perner, et al 200719 | |
| TMPRSS2:ERG | Metastases, hormone naive | 10/34 (29%) | |||
| TMPRSS2:ERG | Metastases, hormone refractory | 3/9 (33%) | |||
| TMPRSS2:ERG | HGPIN | 5/26 (19%) | |||
| TMPRSS2:ERG | BPH | 0/15 (_) | |||
| TMPRSS2:ERG | PIA | 0/38 (_) | |||
| TMPRSS2:ERG | Benign Prostate samples | 0/47 (_) | |||
| TMPRSS2:ERG | PCA | 25/52 (48%) | RT-PCR/FISH | Tu, et al 200720 | |
| TMPRSS2:ERG | PCA, Transurethral resection | 134/445 (30%) | FISH | Attard, et al 200721 | |
| HERV_K_22Q11.23: ETV1 | PCA and Metastases | - | T1:T4, T2:T4 | qRT-PCR/FISH | Tomlins, et al 200722 |
| SLC45A3:ETV1 | PCA and Metastases | - | |||
| C15ORF21:ETV1 | PCA and Metastases | - | |||
| HNRPA2B1:ETV1 | PCA and Metastases | - | |||
| TMPRSS2:ERG | Prostate Biopsies and Post-DRE urine | 17/29 (59%) | RT-PCR | Hessels, et al 200723 | |
| TMPRSS2:ERG | PCA | 81/165 (49%) | RT-PCR, Sequencing | Nam, et al 200724 | |
| TMPRSS2:ERG | PCA, Multifocal | 17/32 (53%) | FISH | Barry, et al 200725 |